#ASH17: The BCMA-targeted CAR-T bb2121 from bluebird and Celgene takes a star turn in the spotlight
A few days ago, Celgene $CELG launched the pivotal Phase II/III study that will dictate the future of the BCMA-targeting bb2121, the CAR-T in-licensed from bluebird bio $BLUE. And if they come close to the data that bluebird has on offer at ASH this weekend, this drug will go on to blaze a big trail in the market as the developers move on to the next big focus in the field of engineered T cells.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.